Merck (MRK.US), Bristol-Myers Squibb (BMY.US) and several other pharmaceutical companies have agreed to lower drug prices in the United States in exchange for tariff exemptions and policy support from the Trump administration.

As President Trump pushes to link drug prices in the United States with lower prices overseas, several large pharmaceutical companies from the United States and Europe recently reached agreements with the White House to voluntarily lower the prices of their drugs sold in the U.S. in exchange for tariff exemptions and policy support. The Trump administration is restarting the "most favored nation drug pricing" policy, attempting to use administrative measures to reduce the high costs of prescription drugs in the United States.